Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interfant-21: Blinatumomab in Infants With KMT2A-rearranged ALL or MPAL
NCT05327894Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2022
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), sponsored by Princess Máxima Center for Pediatric Oncology. Started Dec 2022; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT05327894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327894.